New heart pump could replace ECMO in risky angioplasty
NCT ID NCT07622446
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether a new device called OmniHeart 4.0 can safely support the heart during high-risk angioplasty, compared to the standard ECMO machine. About 254 patients will be randomly assigned to receive either the OmniHeart or ECMO. Researchers will track major heart and brain complications within 30 days to see if the new device is as effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- OmniHeart 4.0 percutaneous ventricular assist device
- What this could lead to
- If successful, this device could offer a less invasive alternative to ECMO for supporting the heart during high-risk angioplasty, potentially reducing complications.
- What could go wrong
- This is an early-stage, non-inferiority trial with 254 participants, so results may not apply to all patients. The device may not perform as well as ECMO, and risks include bleeding, infection, or device failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
254 people
The number who actually took part.
- Started
-
Dec 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- 1. The patient's age is between 18 and 90 years old (inclusive). 2. There is at least one lesion (including primary lesions and restenosis lesions) in the native coronary artery or grafted bypass vessel, and percutaneous coronary intervention (PCI) needs to be performed under hemodynamic support. 3\. The patient meets one of the following conditions: 1. The left ventricular ejection fraction (LVEF) is \<=35%, and the vessel to be treated with interventional therapy is an unprotected left main coronary artery lesion or a lesion with only a single remaining open vessel. 2. The left ventricular ejection fraction (LVEF) is \<=30%, and the vessel to be treated with interventional therapy is a three-vessel coronary artery lesion. Among them, a three-vessel coronary artery lesion is defined as follows: there is at least one significant stenosis in each of the three main epicardial coronary arteries (the left anterior descending branch and/or its branches, the left circumflex branch and/or its branches, the right coronary artery and/or its branches). A significant stenosis is defined as a luminal stenosis \>= 50% (by visual inspection) or complete occlusion, and at least two vessels have a luminal stenosis \>= 70%. For left-dominant coronary arteries, the presence of \>= 50% stenosis in both the left anterior descending branch and the proximal left circumflex branch is also regarded as a three-vessel coronary artery lesion. 4\. The subject or his/her legal guardian is able to understand the purpose of the trial, voluntarily participates in the trial and signs the informed consent form, and is willing to complete the follow-up as required by the trial. Exclusion Criteria: * 1\. Acute ST-segment elevation myocardial infarction within 24 hours before enrollment. 2\. Cardiac arrest occurred within 24 hours before enrollment and cardiopulmonary resuscitation was required. 3\. Emergency thrombolysis was performed before enrollment. 4. Cardiogenic shock exists, and cardiogenic shock is defined as follows: (1) Cardiac index (CI) \< 2.2 L/min/m² and pulmonary capillary wedge pressure (PCWP) \> 15 mmHg; (2) Hypotensive state (systolic blood pressure \< 90 mmHg for more than 30 minutes, or systolic blood pressure maintained \>= 90 mmHg with the support of vasoactive drugs and/or circulatory assist devices), accompanied by end-organ hypoperfusion (urine output \< 30 ml/hour and heart rate \> 60 beats/minute, or cold and clammy extremities). 5\. Left ventricular mural thrombus exists. 6. After aortic valve replacement (including mechanical valves, biological valves), implantation of mechanical circulatory assist devices or cardiac contractile devices. 7\. Moderate or severe aortic stenosis, moderate or severe aortic insufficiency. 8. Severe peripheral arterial stenosis or occlusion lesions that interfere with the implantation of the test device or the control device. 9\. Aortic lesions (including aortic aneurysms, aortic dissections, extreme tortuosity or calcification) that interfere with the operation. 10\. Chronic renal insufficiency (serum creatinine \>= 4 mg/dl), or dialysis treatment is required. 11\. Liver insufficiency (liver transaminase and bilirubin levels are more than 3 times the upper limit of the normal range). 12\. Uncorrected abnormal coagulation function (platelet count \<= 75,000/mm³ or INR \>= 2.0 or fibrinogen \<= 1.5 g/L). 13\. A history of stroke or transient ischemic attack (TIA) within 1 month before enrollment. 14\. Allergic or intolerant to iodine contrast agents, heparin, aspirin, ADP receptor inhibitors, and with a history of heparin-induced thrombocytopenia (HIT) in the past. 15\. Infectious endocarditis exists or is suspected to exist, or there is a systemic active infection. 16\. Currently participating in other drug/device clinical trials and the primary endpoint has not been reached. 17\. Pregnant or lactating women, those with a fertility plan within 1 year or those who are unwilling to take effective contraceptive measures. 18\. Other situations judged by the investigator as not suitable for enrollment that are unforeseen.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High risk pci are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Dynaheart Medtech Co., Ltd
Shanghai, China
-
The Second Affiliated Hospital of Harbin Medical University
Jilin City, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new heart pump outperform the standard during High-Risk angioplasty?
- New study to track survival in High-Risk heart procedures
- Can a heart pump make risky stent placements safer?
- New heart pump could be safer for High-Risk patients
- New heart pump device tested in High-Risk angioplasty patients
- ECMO showdown: which strategy saves more lives in High-Risk heart procedures?